Surgical Management of Distant Metastases

Surgical Oncology Clinics of North America

Volumn 15, Issue 2, 2006, Pages 385-398

  Ollila, David W ^a   Caudle, Abigail S ^a  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA2B INTERFERON; CISPLATIN; DACARBAZINE; GRANULOCYTE COLONY STIMULATING FACTOR; INTERLEUKIN 2; NITROSOUREA; TAXANE DERIVATIVE; TEMOZOLOMIDE; VINBLASTINE;

BRAIN METASTASIS; CANCER CHEMOTHERAPY; CANCER CLASSIFICATION; CANCER LOCALIZATION; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; DOSE RESPONSE; DRUG ACTIVITY; DRUG BIOAVAILABILITY; DRUG DISTRIBUTION; DRUG MEGADOSE; DRUG PENETRATION; DRUG RESPONSE; GAMMA KNIFE RADIOSURGERY; HUMAN; LIVER METASTASIS; LUNG EDEMA; LUNG METASTASIS; LUNG RESECTION; LYMPH NODE METASTASIS; MELANOMA; METASTASIS; PROGNOSIS; RADIOSURGERY; REVIEW; SEPTIC SHOCK; SIDE EFFECT; SKIN METASTASIS; SOFT TISSUE METASTASIS; STEREOTAXIC SURGERY; THORAX RADIOGRAPHY; TREATMENT OUTCOME; VISCERAL METASTASIS;

BRAIN NEOPLASMS; GASTROINTESTINAL NEOPLASMS; HUMANS; LUNG NEOPLASMS; LYMPH NODES; MELANOMA; NEOPLASM METASTASIS; NEOPLASM STAGING; PROGNOSIS; SKIN NEOPLASMS;

EID: 33646055473     PISSN: 10553207     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.soc.2005.12.003     Document Type: Review

References (94)

1. Atkins M., Lotze M., Wiernik P., et al. High dose IL 2 therapy alone results in long-term durable complete responses in patients with metastatic melanoma. [abstract]. Proc Am Soc Clin Oncol 16 (1997) 494a
2. Penhamberger H., Soyer P., Steiner A., et al. Adjuvant interferon alpha-2a treatment in resected primary cutaneous melanoma. [abstract]. Melanoma Res 7 (1977) 31
3. Coates A.S., and Segelov E. Long term response to chemotherapy in patients with visceral metastatic melanoma. Ann Oncol 5 3 (1994) 249-251
4. Cancer A.J.C.O. AJCC cancer staging manual. 6th edition (2002), Springer-Verlag, New York
5. Imamura H., Seyama Y., Kokudo N., et al. Single and multiple resections of multiple hepatic metastases of colorectal origin. Surgery 135 5 (2004) 508-517
6. van der Poel H.G., Roukema J.A., Horenblas S., et al. Metastectomy in renal cell carcinoma: a multicenter retrospective analysis. Eur Urol 35 3 (1999) 197-203
7. Morton D.L., Ollila D.W., Hsueh E.C., et al. Cytoreductive surgery and adjuvant immunotherapy: a new management paradigm for metastatic melanoma. CA Cancer J Clin 49 2 (1999) 101-116 65
8. Carbone P.P., and Costello W. Eastern Cooperative Oncology Group studies with DTIC (NSC-45388). Cancer Treat Rep 60 2 (1976) 193-198
9. Hill II G.J., Krementz E.T., and Hill H.Z. Dimethyl triazeno imidazole carboxamide and combination therapy for melanoma. IV. Late results after complete response to chemotherapy (Central Oncology Group protocols 7130, 7131, and 7131A). Cancer 53 6 (1984) 1299-1305
10. Agarwala S.S., and Kirkwood J.M. Temozolomide, a novel alkylating agent with activity in the central nervous system, may improve the treatment of advanced metastatic melanoma. Oncologist 5 2 (2000) 144-151
11. Agarwala S., Reyderma L., Statkevich P., et al. Pharmacokinetic study of temozolomide penetration into CSF in a patient with dural melanoma. Ann Oncol (1998) (Suppl 4);9:659a
12. Patel J., McCully C., Godwin K., et al. Plasma and cerebrospinal fluid pharmacokinetics of temozolomide. Proc Am Soc Clin Oncol 14 (1995) 461a
13. Middleton M.R., Grob J.J., Aaronson N., et al. Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma. J Clin Oncol 18 1 (2000) 158-166
14. Summers Y., Middleton M., Calvert H., et al. Effect of temozolomide (TMZ) on central nervous system relapse in patients with advanced melanoma. Proc Am Soc Clin Oncol 18 (1999) 531a
15. Kleeberg U.R., Engel E., Israels P., et al. Palliative therapy of melanoma patients with fotemustine. Inverse relationship between tumour load and treatment effectiveness. A multicentre phase II trial of the EORTC-Melanoma Cooperative Group (MCG). Melanoma Res 5 3 (1995) 195-200
16. Einzig A.I., Schuchter L.M., Recio A., et al. Phase II trial of docetaxel (Taxotere) in patients with metastatic melanoma previously untreated with cytotoxic chemotherapy. Med Oncol 13 2 (1996) 111-117
17. Glover D., Glick J.H., Weiler C., et al. WR-2721 and high-dose cisplatin: an active combination in the treatment of metastatic melanoma. J Clin Oncol 5 4 (1987) 574-578
18. Rosenberg S., Yang J., Topaliam S., et al. Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high dose bolus interleukin 2. JAMA 271 (1994) 907-913
19. Keilholz U., Conradt C., Legha S., et al. Results of interleukin-s-based treatment in advanced melanoma: a case record-based analysis of 631 patients. J Clin Oncol 16 (1998) 2921-2929
20. Allen I., Kupelnick B., Kumashiro M., et al. Efficacy of interlekin-2 with or without cisplatin in metastatic melanoma: systemic review and meta-analysis. Cancer Ther 1 (1998) 168-173
21. Keilholz U., Scheibenbogen C., Tilgen W., et al. Interferon-alpha and interleukin-2 in the treatment of metastatic melanoma. Comparison of two phase II trials. Cancer 72 (1993) 607-614
22. Flaherty L., Atkins M., Sosman J., et al. Randomized phase II trial of chemotherapy and outpatient biotherapy with interleukin-2 and interferon alpha in metastatic malignant melanoma. Proc Am Soc Clin Oncol 18 (1999) 2070
23. Agarwala S., Glaspy J., O'Day S., et al. Results from a randomized phase II study comparing combined treatment with histamine dihydrochloride plus interleukin-2 versus interleukin-2 alone in patients with metastatic melanoma. J Clin Oncol 20 (2002) 125-133
24. Keilholz U., Goey S.H., Punt C.J., et al. Interferon alfa-2a and interleukin-2 with or without cisplatin in metastatic melanoma: a randomized trial of the European Organization for Research and Treatment of Cancer Melanoma Cooperative Group. J Clin Oncol 15 7 (1997) 2579-2588
25. Legha S.S., Ring S., Eton O., et al. Development of a biochemotherapy regimen with concurrent administration of cisplatin, vinblastine, dacarbazine, interferon alfa, and interleukin-2 for patients with metastatic melanoma. J Clin Oncol 16 5 (1998) 1752-1759
26. Richards J.M., Gale D., Mehta N., et al. Combination of chemotherapy with interleukin-2 and interferon alfa for the treatment of metastatic melanoma. J Clin Oncol 17 2 (1999) 651-657
27. Gajewski T., and Flickinger S. A phase II study of outpatient chemotherapy using cisplatin and DTIC followed by GM-CSF, IL-2, and IFN-α2b in patients (Pt99s) with metastatic melanoma. [abstract]. Proc Am Soc Clin Oncol 19 (2000) 576a
28. Gibbs P., O'Day S., Richards J., et al. A multicenter phase II study of modified biochemotherapy (BCT) for stage IV melanoma incorporating temozolomide, decrescendo interleukin-2 (IL-2) and GM-CSF. [abstract]. Proc Am Soc Clin Oncol 19 (2000) 572a
29. Legha S.S., Ring S., Bedikian A., et al. Treatment of metastatic melanoma with combined chemotherapy containing cisplatin, vinblastine and dacarbazine (CVD) and biotherapy using interleukin-2 and interferon-alpha. Ann Oncol 7 8 (1996) 827-835
30. Khayat D., Borel C., Tourani J.M., et al. Sequential chemoimmunotherapy with cisplatin, interleukin-2, and interferon alfa-2a for metastatic melanoma. J Clin Oncol 11 11 (1993) 2173-2180
31. O'Day S., Boasberg P., Guo M., et al. Phase II trial of concurrent biochemotherapy (c-BC) with decrescendo interleukin-2 (d-IL-2), tamoxifen (T), and G-CSF support in patients with metastatic melanoma (MM). Proc Am Soc Clin Oncol 16 (1997) 490a
32. Atkins M., Lee S., Flaherty L., et al. A prospective randomized phase III trial of concurrent biochemotherapy (BCT) with cisplatin, vinblastine, dacarbazine (CVD), IL-2 and interferon-alpha-2b (IFN) versus CVD alone in patients with metastatic melanoma (E3695): and ECOG-coordinated intergroup trial. Proc Am Soc Clin Oncol 22 (2003) 708
33. Del Vecchio M., Bajetta E., Vitali M., et al. Multicenter phase III randomized trial of cisplatin, vindesine, and dacarbazine (CVD) versus CVD plus subcutaneous interleukin-2 and interferon-alpha-2b in metastatic melanoma patients. Proc Am Soc Clin Oncol 22 (2003) 709
34. Keilholz U., Punt C., Gore M., et al. Dacarbazine, cisplatin, and IFN - alpha-2b with or without IL-2 in advanced melanoma: final analysis of EORTC randomized phase III trial 189651. Proc Am Soc Clin Oncol 22 (2003) 708
35. Keillholz U., Punt C., and Gore M. Dacarbazine, cisplatin and interferon alfa with or without interleukin-2 in advanced melanoma: interim analysis of EORTC trial 18951. [abstract]. Proc Am Soc Clin Oncol 18 (1990) 2043a
36. Eton O., Legha S.S., Bedikian A., et al. Phase III randomized trial of cisplatin, vinblastine and dacarbazine (CVD) plus interleukin-2 (IL2) and interferon-alpha-2b (INF) versus C D in patients (Pts) with metastatic melanoma. [abstract]. Proc Am Soc Clin Oncol 19 (2000) 552a
37. Paget S. The distribution of secondary growths in cancer of the breast. Lancet 1 (1889) 571
38. Ewing J. Neoplastic diseases: a treatise on tumors. 3rd edition (1928), WB Saunders, Philadelphia
39. Crawford E.D., Eisenberger M.A., McLeod D.G., et al. A controlled trial of leuprolide with and without flutamide in prostatic carcinoma. N Engl J Med 321 7 (1989) 419-424
40. Paridaens R., Dirix L., Lohrisch C., et al. Mature results of a randomized phase II multicenter study of exemestane versus tamoxifen as first-line hormone therapy for postmenopausal women with metastatic breast cancer. Ann Oncol 14 9 (2003) 1391-1398
41. Mattioli R., Lippe P., Massacesi C., et al. Long-survival in responding patients with metastatic breast cancer treated with doxorubicin-docetaxel combination. A multicentre phase II trial. Anticancer Res 24 5B (2004) 3257-3261
42. Petrylak D.P., Tangen C.M., Hussain M.H., et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 351 15 (2004) 1513-1520
43. Ollila D., and Morton D. Surgical resection as the treatment of choice for melanoma metastatic to the lung. Chest Surg Clin N Am 8 1 (1998) 183-196
44. Yasui K., and Shimizu Y. Surgical treatment for metastatic malignancies. Anatomical resection of liver metastasis: indications and outcomes. Int J Clin Oncol 10 2 (2005) 86-96
45. Hofmann H.S., Neef H., Krohe K., et al. Prognostic factors and survival after pulmonary resection of metastatic renal cell carcinoma. Eur Urol 48 1 (2005) 77-81 [discussion 81-2]
46. Inoue M., Ohta M., Iuchi K., et al. Benefits of surgery for patients with pulmonary metastases from colorectal carcinoma. Ann Thorac Surg 78 1 (2004) 238-244
47. Anraku M., Yokoi K., Nakagawa K., et al. Pulmonary metastases from uterine malignancies: results of surgical resection in 133 patients. J Thorac Cardiovasc Surg 127 4 (2004) 1107-1112
48. Balch C., Buzaid A., Soong S., et al. Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. J Clin Oncol 19 (2001) 3635-3648
49. Balch C., Soong S., Gershenwald J., et al. Prognostic factors analysis of 17,600 melanoma patients: validation of the American Joint Committee on Cancer Melanoma Staging System. J Clin Oncol 19 16 (2001) 3622-3634
50. Barth A., Wanek L., and Morton D. Prognostic factors in 1521 melanoma patients with distant metastases. J Am Coll Surg 181 (1995) 193-201
51. Gadd M., and Coit D. Recurrence patterns and outcome in 1019 patients undergoing axillary or inguinal lymphadenopathy for melanoma. Arch Surg 127 (1992) 1412-1416
52. Feun L., Gutterman J., Burgess M., et al. The natural history of resectable metastatic melanoma (Stage IV A melanoma). Cancer 50 (1982) 1656-1663
53. Balch C., Soong S., Murad T., et al. A multifactorial analysis of melanoma. IV. Prognostic factors in 200 melanoma patients with distant metastases (stage III). J Clin Oncol 1 (1983) 126-134
54. Eton O., Legha S., Moon T., et al. Prognostic factors for survival of patients treated systemically for disseminated melanoma. J Clin Oncol 16 (1998) 1103-1111
55. Markowitz J., Cosimi L., Carey R., et al. Prognosis after initial recurrence of cutaneous melanoma. Ann Surg 214 (1991) 703-707
56. Bowen G.M., Chang A.E., Lowe L., et al. Solitary melanoma confined to the dermal and/or subcutaneous tissue: evidence for revisiting the staging classification. Arch Dermatol 136 (2000) 1397-1399
57. Wong S.L., and Coit D.G. Role of surgery in patients with stage IV melanoma. Curr Opin Oncol 16 2 (2004) 155-160
58. Gorenstein L.A., Putnam J.B., Natarajan G., et al. Improved survival after resection of pulmonary metastases from malignant melanoma. Ann Thorac Surg 52 2 (1991) 204-210
59. Harpole Jr. D.H., Johnson C.M., Wolfe W.G., et al. Analysis of 945 cases of pulmonary metastatic melanoma. J Thorac Cardiovasc Surg 103 4 (1992) 743-748 [discussion: 748-50]
60. Tafra L., Dale P.S., Wanek L.A., et al. Resection and adjuvant immunotherapy for melanoma metastatic to the lung and thorax. J Thorac Cardiovasc Surg 110 1 (1995) 119-128 [discussion: 129]
61. Pastorino U., Buyse M., Friedel G., et al. Long term results of lung metastectomy: prognostic analyses based on 5206 cases. J Thorac Cardiovasc Surg 113 (1997) 37-49
62. Leo F., Cagini L., Rocmans P., et al. Lung metastases from melanoma: when is surgical treatment warranted?. Br J Cancer 83 (2000) 569-572
63. Karp N., Boyd A., DePan H., et al. Thoracotomy for metastatic malignant melanoma of the lung. Surgery 107 (1990) 256-261
64. Karakousis C., Velez A., Driscoll B., et al. Metastectomy in malignant melanoma. Surgery 115 (1994) 295-302
65. La Hei E., Thompson J., McCaughan B., et al. Surgical resection of pulmonary metastatic melanoma: a review of 83 thoracotomies. Asia Pacific Heart J 5 (1996) 111-114
66. Ollila D.W., Stern S.L., and Morton D.L. Tumor doubling time: a selection factor for pulmonary resection of metastatic melanoma. J of Surg Onc 69 4 (1998) 206-211
67. Das Gupta T., and Brasfield R. Metastatic melanoma of the gastrointestinal tract. Arch Surg 88 (1964) 969-973
68. Patel J., Didolkar M., Pickren J., et al. Metastatic pattern of malignant melanoma. A study of 216 autopsy studies. Am J Surg 135 (1978) 807-810
69. de la Monte S., Moore G., and Hutchins G. Patterned distribution of metastasis from malignant melanoma in humans. Cancer Res 43 (1983) 3427-3433
70. Ricaniadis N., Konstadoulakis M., Walsh D., et al. Gastrointestinal metastases from malignant melanoma. Surg Oncol 4 (1995) 105-110
71. Branum G., and Seigler H. Role of surgical intervention in the management of intestinal metastases from malignant melanoma. Am J Surg 162 5 (1991) 428-431
72. Wood T., DiFronzo L., Rose D., et al. Does complete resection of melanoma metastatic to solid intra-abdominal organs improve survival?. Ann Surg Oncol 8 (2001) 658-662
73. Agrawal S., Yao T., and Coit D. Surgery for melanoma metastatic to the gastrointestinal tract. Ann Surg Oncol 6 (1999) 336-344
74. Ollila D., Essner R., Wanek L., et al. Surgical resection for melanoma metastatic to the gastrointestinal tract. Arch Surg 131 (1996) 975-979
75. Haigh P., Essner R., Wardlaw J., et al. Long-term survival after complete resection of melanoma metastatic to the adrenal gland. Ann Surg Oncol 6 (1999) 633-639
76. Rose D., Essner R., Hughes T., et al. Surgical resection for metastatic melanoma to the liver: the John Wayne Cancer Institute and Sydney Melanoma Unit Experience. Arch Surg 136 8 (2001) 950-955
77. Holder Jr. W.D., White Jr. R.L., Zuger J.H., et al. Effectiveness of positron emission tomography for the detection of melanoma metastases. Ann Surg 227 5 (1998) 764-769 [discussion: 769-71]
78. Rinne D., Baum R.P., Hor G., et al. Primary staging and follow-up of high risk melanoma patients with whole-body 18F-fluorodeoxyglucose positron emission tomography: results of a prospective study of 100 patients. Cancer 82 9 (1998) 1664-1671
79. Mendez I., and Del Maestro R. Cerebral metastases from malignant melanoma. Can J Neurol Sci 15 (1988) 119-123
80. Sampson J., Carter J., Friedman A., et al. Demographics, prognosis, and therapy in 702 patients with brain metastases from malignant melanoma. J Neurosurg 88 (1998) 11-20
81. Amer M., Al-Sarraf M., and Vaitkevicius V. Clinical presentation, natural history, and prognostic factors in advanced malignant melanoma. Surg Gynecol Obstet 149 (1979) 687-692
82. Johnson J., and Young B. Demographics of brain metastasis. Nerosurg Clin North Am 7 (1996) 337-344
83. Yu C., Chen J.C., Apuzzo M., et al. Metastatic melanoma to the brain: prognostic factors after gamma knife radiosurgery. Int J Radiat Oncol Biol Phys 52 (2002) 1277-1287
84. Budman D., Carmacho E., and Wittes R. The current causes of death in patients with malignant melanoma. Eur J Surg Oncol 14 (1978) 327-330
85. Radbill A., Fiveash J., Falkenberg E., et al. Initial treatment of melanoma brain metastases using gamma knife radiosurgery: an evaluation of efficacy and toxicity. Cancer 101 4 (2004) 825-833
86. Wronski M., and Arbit E. Surgical treatment of brain metastases from melanoma: a retrospective study of 91 patients. J Neurosurg 93 (2000) 9-18
87. Oredsson S., Ingvar C., Strombald L., et al. Palliative surgery for brain metastases of malignant melanoma. Eur J Surg Oncol 16 (1990) 451-456
88. Brega K., Robinson W., Winston K., et al. Surgical treatment of brain metastases in malignant melanoma. Cancer 66 (1990) 2105-2110
89. Tarhini A., and Agarwala S. Management of brain metastases in patients with melanoma. Curr Opin Oncol 16 2 (2004) 161-166
90. Lavine S., Petrovich Z., and Cohen-Gadol A. Gamma knife radiosurgery for metastatic melanoma: an analysis of survival, outcome, and complications. Neurosurgery 44 (1999) 59-64
91. Garbe C., and Schadendorf D. Surveillance and follow-up examinations in cutaneous melanoma. Onkologie 26 3 (2003) 241-246
92. Christianson D.F., and Anderson C.M. Close monitoring and lifetime follow-up is optimal for patients with a history of melanoma. Semin Oncol 30 3 (2003) 369-374
93. Essner R., Lee J.H., Wanek L.A., et al. Contemporary surgical treatment of advanced-stage melanoma. Arch Surg 139 9 (2004) 961-966 [discussion: 966-7]
94. Gutman H., Hess K., Kokoysakis J., et al. Surgery for abdominal metastases of cutaneous melanoma. World J Surg 25 (2001) 750-758